MedTrace Logo

Effectiveness of Nebulized Dexmedetomidine for Treatment of Obstetric Post-Dural Puncture Headache

NCT04327726 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2021-05-12

No results posted yet for this study

Summary

Postdural puncture headache (PDPH) is a common complication, following neuraxial techniques. The obstetric population is particularly prone to PDPH. Therefore, treatment of PDPH is a key issue in obstetric anesthesia.

Dexmedetomidine is a highly selective, centrally acting α2-adrenergic agonist with analgesic and anxiolytic effects. Moreover, it decreases cerebral blood flow (CBF) in humans and animals secondary to cerebrovascular vasoconstriction. It has been used via the intranasal and inhalational routes for many purposes including premedication, sedation and postoperative analgesia. Because of its desirable properties, we hypothesized that dexmedetomidine nebulization could be effective in the treatment of patients suffering from PDPH after caesarean section.

Conditions

  • Post-Dural Puncture Headache

Interventions

DRUG

Dexmedetomidine Nebulization

ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment

OTHER

0.9% Saline Nebulization

nebulization of 4mL 0.9% saline

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Sherif M Mowafy, MD · Anesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University

  • Shereen E Abd Ellatif, MD · Anesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2021-01-30
Completion
2021-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04327726 on ClinicalTrials.gov